Diagnostic News and Research

RSS

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD

Aeterna Zentaris Inc. today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD).

27 Jul 2011

Patients with MTBI exhibit abnormal functional connectivity in the thalamus

A new study has found that patients with mild traumatic brain injury (MTBI) exhibit abnormal functional connectivity in the thalamus, a centrally located relay station for transmitting information throughout the brain.

26 Jul 2011

Sediments buried beneath the Black Sea contain ancient virus and host DNA

A scientist analyzing ancient plankton DNA signatures in sediments of the Black Sea has found that the same genetic populations of a virus and its algal host can persist--and coexist--for centuries.

26 Jul 2011

Women & Infants creates fully integrated center for high-risk pregnancy

Every pregnancy deserves special treatment. But when a woman with a normal pregnancy has a complication or a woman with a medical issue becomes pregnant, she needs highly specialized care.

26 Jul 2011

Researchers identify elusive gene responsible for Grey Platelet Syndrome

Researchers have identified an elusive gene responsible for Grey Platelet Syndrome, an extremely rare blood disorder in which only about 50 known cases have been reported. As a result, it is hoped that future cases will be easier to diagnose with a DNA test.

26 Jul 2011

Phadia demonstrates ImmunoCAP Molecular Allergy testing at AACC 2011

Today, at the 2011 American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, Phadia, the global leader in allergy and autoimmune disease-related diagnostics, demonstrates how ImmunoCAP Molecular Allergy can help improve the diagnosis and management of food allergy.

26 Jul 2011

Waters receives CE mark for MassTrak Immunosuppressants XE Kit

Waters Corporation (NYSE: WAT) today announced that its MassTrak™ Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus in liver and kidney transplant patients and everolimus in adult kidney and cardiac transplant patients from human whole blood samples as an aid in the management of immunosuppressant drug therapy.

25 Jul 2011

New method for detecting breast cancer at 'stage 0'

RNL Natural Co., Ltd, a leading biotech company specialized in adult stem cell therapeutics affiliated with RNL BIO Co., Ltd., introduced on June 22, 2011 a new method of detecting breast cancer as early as at 'stage 0' through breath VOCs.

25 Jul 2011

OCD introduces VITROS 4600 Chemistry System for high-volume laboratories

Ortho Clinical Diagnostics (OCD) today announced the launch of the VITROS® 4600 Chemistry System, a state-of-the-art analyzer that delivers high-quality, reliable test results for mid- to high-volume laboratories using the same core technologies that drive reliability and efficiency throughout OCD's portfolio of products.

From Ortho-Clinical Diagnostics, Inc. 22 Jul 2011

IDEXX Laboratories second quarter revenues increase 13% to $317.9 million

IDEXX Laboratories, Inc., today reported that revenues for the second quarter of 2011 increased 13% to $317.9 million, from $281.5 million for the second quarter of 2010. Organic revenue growth, as defined below, was 8%.

22 Jul 2011

The Joint Commission certifies 7 disease-specific programs at Children's Medical Center

The Joint Commission has certified seven disease-specific programs at Children's Medical Center Dallas, www.childrens.com. Children's is the only pediatric hospital in the United States with more than two such designations of excellence, making the Dallas hospital a leader in health care reform.

22 Jul 2011

Leading cancer specialists and researchers establish Australia’s first comprehensive ‘Cancer Survivors Centre’

Australia’s first comprehensive treatment and research centre for the growing number of cancer survivors will be announced at the annual Ride for Life luncheon at NSW Parliament House today.

22 Jul 2011

Randox win Premier Healthcare Alliance contract for Quality Control

Randox Laboratories Ltd is proud to announce that in April 2011 we signed a multi-year agreement with the Premier Healthcare Alliance for the supply of Acusera Quality Control (QC) materials. The agreement will provide the 90,000 plus Premier members with access to our extensive range of quality control products and the benefits they offer clinical laboratories. When asked about the new agreement Laura Coyle Randox Business Manager for the USA revealed that ‘We look forward to strengthening our relationship with Premier and providing added value to their members’.

From Randox Laboratories Ltd. 21 Jul 2011

WHO warning increases opportunity for Biomagnetics urine based TB assay

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced that the World Health Organization ("WHO") on Sunday July 17, 2011 warned that the widely used blood tests to detect tuberculosis ("TB") are unreliable and "dangerous" to patients because they produce too many false negatives and positives.

21 Jul 2011

High methodological quality studies of PET in malignant melanoma patients needed

The relevance of positron emission tomography (PET) alone or in combination with computed tomography (CT) in patients with malignant melanoma cannot be currently assessed due to a lack of meaningful studies. This is the result of a final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 20 July 2011.

21 Jul 2011

New rapid test accurately distinguishes bacterial and viral infections

Researchers at Ben-Gurion University of the Negev (BGU) have developed a new test that quickly and accurately distinguishes between bacterial and viral infections in as little as five hours.

21 Jul 2011

Study examines cost-effectiveness of MS drugs in the U.S.

A new study examining the cost-effectiveness of drugs to treat multiple sclerosis (MS) in the United States finds that the health gains from these drugs come at a very high cost compared to basic therapy to control the symptoms of MS and compared to treatments for other chronic diseases.

21 Jul 2011

MDL announces HPV-16 Status reflex test

Medical Diagnostic Laboratories, L.L.C. (MDL) is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

20 Jul 2011

Quest Diagnostics second quarter revenues increase 1.5% to $1.9 billion

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced today that for the second quarter ended June 30, 2011, adjusted income from continuing operations was $179 million, or $1.12 per share.

From Quest Diagnostics 20 Jul 2011